Search results
Results From The WOW.Com Content Network
Price Action: BSX stock is down 1.66% at $83.16 at last check Wednesday. Read Next: CDW Shares Dip As Q3 Sales Miss Amid Weak Hardware Demand And Customer Delays
The stock of Boston Scientific (NYSE:BSX, 30-year Financials) gives every indication of being fairly valued, according to GuruFocus Value calculation.
On May 19, 1992, Boston Scientific launched an initial public offering of 23.5 million shares, of which 18.8 million were offered in the U.S. and 4.7 million were offered outside the U.S. The initial offering amounted to 23% of Boston Scientific's outstanding stock. The opening price was $17 per share. [6]
For premium support please call: 800-290-4726 more ways to reach us
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
On December 5, 2005, Boston Scientific made a surprise unsolicited $24.6 billion bid to acquire Guidant, offering $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share. Guidant's stock price rose 10% on the news.
In this article we will check out the progression of hedge fund sentiment towards Boston Scientific Corporation (NYSE:BSX) and determine whether it is a good investment right now.
A global medical technology company, Boston Scientific (S&P 500: BSX), is focused on transforming lives through innovative medical solutions to improve the health of patients globally. Accretive ...